Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases
Status:
Recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
This study intends to conduct a small, prospective, single-center clinical study to explore
and evaluate the efficacy and safety of pyrrotinib combined with capecitabine and bevacizumab
in HER2-positive advanced breast cancer with brain metastases.The overall objective is to
provide a new drug regimen for HER2 positive breast cancer patients with brain metastases by
balancing survival benefits and patient quality of life.